vs
AVINO SILVER & GOLD MINES LTD（ASM）与Ginkgo Bioworks Holdings, Inc.（DNA）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是AVINO SILVER & GOLD MINES LTD的1.6倍（$33.4M vs $21.0M），AVINO SILVER & GOLD MINES LTD同比增速更快（44.0% vs -23.8%），过去两年AVINO SILVER & GOLD MINES LTD的营收复合增速更高（51.1% vs -6.2%）
阿维诺金银矿业有限公司是一家加拿大矿业企业，主要从事银、金、铜等贵金属及基本金属的勘探、开发与生产，核心运营资产为位于墨西哥杜兰戈州的旗舰阿维诺矿区，产品供应全球大宗商品市场。
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
ASM vs DNA — 直观对比
营收规模更大
DNA
是对方的1.6倍
$21.0M
营收增速更快
ASM
高出67.8%
-23.8%
两年增速更快
ASM
近两年复合增速
-6.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0M | $33.4M |
| 净利润 | $7.7M | — |
| 毛利率 | 47.1% | — |
| 营业利润率 | — | -211.9% |
| 净利率 | 36.6% | — |
| 营收同比 | 44.0% | -23.8% |
| 净利润同比 | 558.9% | — |
| 每股收益（稀释后） | $0.05 | $-1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMDNA
| Q4 25 | — | $33.4M | ||
| Q3 25 | $21.0M | $38.8M | ||
| Q2 25 | $21.8M | $49.6M | ||
| Q1 25 | $18.8M | $48.3M | ||
| Q4 24 | — | $43.8M | ||
| Q3 24 | $14.6M | $89.0M | ||
| Q2 24 | $14.8M | $56.2M | ||
| Q1 24 | $12.4M | $37.9M |
净利润ASMDNA
| Q4 25 | — | — | ||
| Q3 25 | $7.7M | $-80.8M | ||
| Q2 25 | $2.9M | $-60.3M | ||
| Q1 25 | $5.6M | $-91.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.2M | $-56.4M | ||
| Q2 24 | $1.2M | $-217.2M | ||
| Q1 24 | $599.0K | $-165.9M |
毛利率ASMDNA
| Q4 25 | — | — | ||
| Q3 25 | 47.1% | — | ||
| Q2 25 | 46.9% | — | ||
| Q1 25 | 56.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 39.1% | — | ||
| Q2 24 | 31.8% | — | ||
| Q1 24 | 18.9% | — |
营业利润率ASMDNA
| Q4 25 | — | -211.9% | ||
| Q3 25 | — | -231.8% | ||
| Q2 25 | — | -132.1% | ||
| Q1 25 | — | -184.1% | ||
| Q4 24 | — | -236.3% | ||
| Q3 24 | — | -62.0% | ||
| Q2 24 | — | -396.7% | ||
| Q1 24 | — | -469.1% |
净利率ASMDNA
| Q4 25 | — | — | ||
| Q3 25 | 36.6% | -207.9% | ||
| Q2 25 | 13.1% | -121.6% | ||
| Q1 25 | 29.8% | -188.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.0% | -63.3% | ||
| Q2 24 | 8.4% | -386.4% | ||
| Q1 24 | 4.8% | -437.3% |
每股收益（稀释后）ASMDNA
| Q4 25 | — | $-1.41 | ||
| Q3 25 | $0.05 | $-1.45 | ||
| Q2 25 | $0.02 | $-1.10 | ||
| Q1 25 | $0.04 | $-1.68 | ||
| Q4 24 | — | $-1.91 | ||
| Q3 24 | $0.01 | $-1.08 | ||
| Q2 24 | $0.01 | $-4.23 | ||
| Q1 24 | $0.00 | $-3.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.3M | $422.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $182.1M | $508.6M |
| 总资产 | $221.9M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASMDNA
| Q4 25 | — | $422.6M | ||
| Q3 25 | $57.3M | $495.5M | ||
| Q2 25 | $37.3M | $559.4M | ||
| Q1 25 | $26.6M | $325.3M | ||
| Q4 24 | — | $561.6M | ||
| Q3 24 | $7.8M | $616.2M | ||
| Q2 24 | $5.3M | $730.4M | ||
| Q1 24 | $3.5M | $840.4M |
股东权益ASMDNA
| Q4 25 | — | $508.6M | ||
| Q3 25 | $182.1M | $559.8M | ||
| Q2 25 | $144.8M | $613.0M | ||
| Q1 25 | $132.3M | $647.4M | ||
| Q4 24 | — | $716.1M | ||
| Q3 24 | $114.5M | $797.9M | ||
| Q2 24 | $112.2M | $833.1M | ||
| Q1 24 | $107.8M | $987.3M |
总资产ASMDNA
| Q4 25 | — | $1.1B | ||
| Q3 25 | $221.9M | $1.2B | ||
| Q2 25 | $174.7M | $1.2B | ||
| Q1 25 | $157.7M | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $135.4M | $1.5B | ||
| Q2 24 | $133.7M | $1.6B | ||
| Q1 24 | $128.6M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.3M | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.7M |
| 自由现金流率自由现金流/营收 | — | -142.8% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 1.08× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASMDNA
| Q4 25 | — | $-47.7M | ||
| Q3 25 | $8.3M | $-31.6M | ||
| Q2 25 | $8.3M | $-40.3M | ||
| Q1 25 | $758.0K | $-51.5M | ||
| Q4 24 | — | $-42.4M | ||
| Q3 24 | $4.1M | $-103.5M | ||
| Q2 24 | $1.1M | $-84.4M | ||
| Q1 24 | $2.3M | $-89.3M |
自由现金流ASMDNA
| Q4 25 | — | $-47.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-40.3M | ||
| Q1 25 | — | $-59.1M | ||
| Q4 24 | — | $-56.1M | ||
| Q3 24 | — | $-118.6M | ||
| Q2 24 | — | $-111.4M | ||
| Q1 24 | — | $-96.0M |
自由现金流率ASMDNA
| Q4 25 | — | -142.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -81.2% | ||
| Q1 25 | — | -122.4% | ||
| Q4 24 | — | -128.0% | ||
| Q3 24 | — | -133.2% | ||
| Q2 24 | — | -198.2% | ||
| Q1 24 | — | -252.9% |
资本支出强度ASMDNA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 15.8% | ||
| Q4 24 | — | 31.3% | ||
| Q3 24 | — | 16.9% | ||
| Q2 24 | — | 48.1% | ||
| Q1 24 | — | 17.7% |
现金转化率ASMDNA
| Q4 25 | — | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.55× | — | ||
| Q2 24 | 0.87× | — | ||
| Q1 24 | 3.92× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASM
暂无分部数据
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
